@article{APS7051,
author = {Zhi-qiang Ling and Chun-jian Qi and Xiao-xiao Lu and Li-juan Qian and Lin-hui Gu and Zhi-guo Zheng and Qiang Zhao and Shi Wang and Xian-hua Fang and Zhi-xing Yang and Jian Yin and Wei-min Mao},
title = {Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay},
journal = {Acta Pharmacologica Sinica},
volume = {33},
number = {3},
year = {2016},
keywords = {},
abstract = {Aim: Current chemotherapy for esophageal cancer is conducted on the basis of empirical information from clinical trials, which fails to take into account the known heterogeneity of chemosensitivity between patients. This study was aimed to demonstrate the degree of heterogeneity of chemosensitivity in esophageal cancers.
Methods: A total of 42 esophageal cancer specimens were collected. The heterogeneity of chemosensitivity in esophageal cancer specimens was examined using an ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
Results: Thirty eight specimens produced evaluable results (90.5%). The most active single agent tested was nedaplatin, to which 28.9% of samples were sensitive. Combinations of chemotherapy agents exhibited much higher sensitivity: cisplatin+paclitaxel was sensitive in 16 of 38 (42.1%) of samples, while nedaplatin+paclitaxel was more effective, which was sensitive in 20 of 38 cases (52.6%).
Conclusion: There was a marked heterogeneity of chemosensitivity in esophageal cancer. Chemosensitivity testing may provide a practical method for testing new regimens before clinical trials in esophageal cancer patients.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/7051}
}